Thus, we will discuss the possibility of using PARP inhibitors in the treatment of not only familial cancers, but also as part of a combination therapy or preventative reagent in non-familial cancers, and potentially in inflammatory diseases which carry a high risk for cancer development. Here, PARP1 is linked to cancer.